David Peereboom
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, David Peereboom sits in the upper quartile of US sponsors by registered trial count (#3,661 of 15,742 sponsors by registered trial count).
David Peereboom: 3 sponsored US clinical trials, none currently recruiting.
David Peereboom sponsors 3 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 2 completed. 0 of these trials are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioblastoma, with 1 trials.
Upper-quartile sponsor footprint
David Peereboom sits in the upper quartile of the sponsor corpus (#3,661 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
3 total, page 1 of 1
Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM
NCT03452579
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
NCT04013672
Radiation Therapy, Temozolomide, and Erlotinib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
NCT00274833
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 3 |
Therapeutic Areas
How the David Peereboom early-phase archive is shaped
3 indexed studies, none listed as recruiting (0% open); 2 completed (67%).
Phase mix: 0 late (III/IV) vs 3 early (I/II) (early-phase heavy).
Top condition: Glioblastoma (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
David Peereboom: archived-pipeline peers nationwide
Peers matched on 3 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
David Peereboom sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 3 archived trials
- 10xBio · 3 trials · 0% recruiting
- 22nd Century Group · 3 trials · 0% recruiting
- AA Secord · 3 trials · 0% recruiting
- AAADRS Clinical Research Center · 3 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
- 3 Waves Wellness · 0% recruiting · 2 trials
- 3EO Health · 0% recruiting · 2 trials
Related
What to do with this David Peereboom page
3 registered trials is a research-attention snapshot, not an endorsement of David Peereboom or any single study.
- None of David Peereboom's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Glioblastoma is the condition David Peereboom studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioblastoma trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
David Peereboom pipeline card: 3 registered trials from official public datasets.Report a data error.